Medical complications of alcohol use disorder

To characterize medical comorbidity of patients requesting treatment for alcohol use disorder: Alcoholic liver disease, immunological alterations, malnutrition, cardiovascular risk, neurological risk and viral infections, amongst other pathologies being studied.

Alcohol-associated morbidity and mortality

To describe the long-term evolution and outcomes of patients who abuse drugs or alcohol and knowing the causes of death as a function of comorbidity.

Therapeutic interventions in alcohol use disorder

Monitoring viral infections (HCV, HIV, HBV) in patients with SUD

• To establish diagnostics, clinical evaluation and access to treatment of common viral infections (i.e., HIV, Hepatitis B and C) in patients with substance use disorder
• To analyze the risk of developing disease such as  AIDS, liver cirrhosis or cancer and death

Intestinal permeability, systemic inflammation and cardiometabolic alterations

To study markers of inflammation, intestinal permeability and oxidative stress in a cohort of patients with alcohol use disorder.

Immune alterations associated with alcohol use disorder

To characterize the alterations of cellular immunity subsets in patients with alcohol use disorder according to the severity of alcoholic liver disease and to determine the molecular mechanisms that make alcohol use disorder at risk of immunodeficiency.

Alcoholic hepatitis: immunophenotypes, plasmatic protein expression and RNA sequencing at early diagnose of patients with alcohol use disorder

PI: Paola Zuluaga, Robert Muga
Programme: Fondo de Investigación en Salud (FIS)
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI20/00883

This research line analyses immunity activation phenotypes, the lymphocyte differentiation, and the role of specific serum proteins involved in the hepatic inflammatory reaction of patients with Alcohol Use Disorder (AUD).

Intestinal microbiota and alcohol use disorder. Impact of sex and concomitant use of cocaine and/or cannabis

PI: Daniel Fuster
Programme: Fondo de Investigación en Salud (FIS)
Funding agency: Ministerio de Sanidad, Plan Nacional Sobre Drogas.​​​​​
Agency code: PNSD 2020I024

This research analyses immunity activation phenotypes, the lymphocyte differentiation, and the role of specific serum proteins involved in the hepatic inflammatory reaction of patients with Alcohol Use Disorder (AUD).

Multicentric study of adult people with alcohol use disorder that seek treatment for the first time (CohRTA Study)

PI: Robert Muga
Funding agency: Ministerio de Sanidad, Plan Nacional Sobre Drogas.​​​​​
Agency code: PNSD 2018I020.

The objective of this study conducted in 9 Spanish centres is to collect clinical information in a wide series of AUD patients that start treatment for the first time and to analyse its impact on health.

Red de Trastornos Adictivos. Redes Temáticas de Investigación Cooperativa en Salud (RETICS)

PI: Robert Muga
Funding agency: Instituto de Salud Carlos III (ISCIII). Ministerio de Ciencia y Competitividad
Agency code: RD16/0017/0003

Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS)

PI: Robert Muga
Funding agency: Instituto de Salud Carlos III (ISCIII), financed by NextGenerationEU
Agency code: RD21/0009/0004

Ajuts per donar suport a les activitats dels grups de recerca (SGR 2017-2019). Grup de Recerca Consolidat

PI: Robert Muga
Funding agency: Departament de Recerca i Universitats, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR)
Agency code: 2021 SGR 00945

Uso inapropiado de opioides en pacientes con cáncer de pulmón

PI: Teresa Morán
Funding agency:  Sociedad Española de Oncología Médica

Diferencias en susceptibilidad genética a trastornos por uso de alcohol en función del sexo/género: implicaciones en tratamiento y pronóstico

PI: Javier Costas
Funding agency: Ministerio de Sanidad, Servicios Sociales e Igualdad, Plan Nacional Sobre Drogas
Agency code: 2021 SGR 00945

This project aims to identify genetic evidences of the prevalence of different pathways towards Alcohol Use Disorder (AUD) in men and women and to detect interactions between genotype (by Polygenic Risk Scores) and sex/gender in predicting the severity of AUD, polydrug use and psychiatric comorbidity